Tandem Meetings 2023 | Incidence of second primary malignancies in lymphoma survivors
Sanjal Desai, MD, University of Minnesota Medical School, Minneapolis, MN, describes the results of a prospective cohort study exploring the incidence and factors associated with the risk of developing a second primary malignancy (SPM) in lymphoma survivors. When compared with the general population, lymphoma survivors had a lower likelihood of developing an SPM and a solid tumor, but had a higher chance of developing a therapy-related neoplasm. Treatment with chemotherapy and alkylating agents was associated with a higher likelihood of developing a second malignancy. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
